logo

Spine Specialists Discredit Medtronic Bone Growth Product

June 29th, 2011

“It harms patients to have biased and corrupted research published…It harms patients to have unaccountable special interests permeate medical research,” read an excerpt from an article concerning the Medtronic bone growth product called Infuse published in a special issue of The Spine Journal entirely dedicated to the matter. In the journal, a series of doctors criticize the research done on the Medtronic product claiming that researchers concealed complications, and minimized risks they encountered during clinical trials.

The New York Times wrote that “It is extremely rare for researchers to publicly chastise colleagues, and editors of leading medical journals said they could not recall an instance in which a publication had dedicated an entire issue for such a singular purpose.”

Infuse is a product developed by Medtronic for the purpose of facilitating bone growth. It is composed of a bioengineered material, and the product is used in an estimated 108,000 spinal fusions in the United States each year.

“The spine care field is currently at a precarious intersection of professionalism, morality and public safety,” said the editor of the special edition of The Spine Journal, Dr. Christopher M. Bono. “As physicians and journal editors, we felt an obligation to present a thorough examination of this controversial issue.”

In 2002, Medtronic reported studies done on Infuse to the FDA as required for approval. The FDA responded by stating that the risk of complications were severe enough to warrant printing them on the label. During the last decade, however, many studies were done on the product, and the ones that were funded by Medtronic concluded that there were no significant risks associated with using Infuse.

No word yet as to how this uncharacteristic outcry by the medical community will affect Medtronic or other medical professionals considering prescribing Infusion

Latest News from Pharma-Watch

FDA convenes to determine Fosamax bone fracture dangers

The New York Times Reports: In light of evidence linking the long-term use of Fosamax and femur fractures, the FDA said it plans to convene Friday to determine whether it will recommend suspending the use of the osteoporosis drug.

Spine Specialists Discredit Medtronic Bone Growth Product

June 29th, 2011 “It harms patients to have biased and corrupted research published…It harms patients to have unaccountable special interests permeate medical research,” read an excerpt from an

CT Brain Perfusion Scan Risks

The FDA released an advisory to consumers in October regarding the CT Bran Profusion Scan manufactured by GE. The advisory states that the scans default radiation therapy is set to high for most patient

Risk of death found in sleeping pill use -- Scripps

Scripps Study: Sleeping pills believed a cause of 500,000 premature deaths annually (March 1, 2012) Pick 10 people at random and ask them if they take sleeping pills. Chances are at least one of them

FDA pulls approval of Avastin breast cancer drug

Avastin no longer allowed for breast cancer The U.S. Food & Drug Administration has revoked its approval of Avastin after concluding the metastatic breast cancer treatment did nothing to control tumor